Product Description
Cidofovir is a nucleoside analogue and antiviral agent which is used in therapy of serious cytomegalovirus infections in immunocompromised patients. Cidofovir has been associated with mild-to-moderate serum aminotransferase elevations during intravenous therapy, but has not been convincingly linked to cases of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cidofovir)
Mechanisms of Action: DNA Polymerase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Belgium | Brazil | Canada | Czech | Denmark | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Italy | Netherlands | Norway | Peru | Portugal | Russia | Serbia | Slovenia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TreatAIN | P3 |
Active, not recruiting |
HIV Infections |
2022-02-03 |